Introduction
============

The first observations on the existence of "nervous steroids" appeared in the early 1980s, introducing the novel concept that some hormonal steroids may be synthesized *de novo* in the nervous system. Baulieu ([@B7]) coined the term "neurosteroids" in order to define such molecules. Over the years, the importance of such endogenous steroids in the control of both the central nervous system (CNS) and peripheral nervous system (PNS) has become increasingly apparent. However, most of the observations were made through investigations into their role in neuronal cells. Equally important are the putative effects that neurosteroids may directly exert on glial cells by regulating their physiological functions, or even indirectly through the complex interactions with neuronal cells.

It is now generally believed that central (i.e., astrocytes, oligodendrocytes) and peripheral glial cells (i.e., Schwann cells, SC) are fundamental for the regulation of neuronal activity. They support neuron metabolism and survival, they can uptake and produce neurotransmitters and they are also able to synthesize neurosteroids (Celotti et al., [@B24]; Melcangi et al., [@B98]). Glial cells, indeed, possess all the enzymatic pathways and the synthetic machinery required to produce steroids (that is the P450 cholesterol side-chain cleavage enzyme, P450SCC; 17α-hydroxysteroid-dehydrogenase, 17α-HSD; 3β-hydroxysteroid-dehydrogenase, 3β-HSD and other enzymes), or to convert them into neuroactive metabolites (Mellon et al., [@B114]). In particular, the enzymatic complex formed by the 5α-reductase (5α-R) and the 3α-hydroxysteroid-dehydrogenase (3α-HSD) enzymes has been characterized in several areas of the human brain (Steckelbroeck et al., [@B141]) and in the PNS (Melcangi et al., [@B101], [@B103], [@B109]; Celotti et al., [@B24]). The combined action of these two enzymes catalyzes the conversion of some native steroids, such as progesterone (P), into their more active 5α-3α-reduced metabolites, that is into "neurosteroids." This enzymatic complex is extremely versatile since every steroid possessing the δ4-3keto configuration could potentially undergo the 5α-reduction and subsequently be subjected to 3α-hydroxylation (Celotti et al., [@B24]; Melcangi et al., [@B109], [@B112]). By analyzing the ability of purified primary cell cultures of neurons, astrocytes (type 1 and type 2 astrocytes) or oligodendrocytes to metabolize testosterone (T; Melcangi et al., [@B100], [@B104], [@B105]), it has been demonstrated that neurons possess significantly higher amounts of 5α-R activity compared to astrocytes and oligodendrocytes (Melcangi et al., [@B104], [@B105]). Interestingly, the simultaneous presence of neurons and type 1 astrocyte cultures stimulates the 5α-R activity (Melcangi et al., [@B99]), indicating a possible interaction of these cells in the metabolism of neurosteroids. It is also reasonable to speculate that the metabolism of neurosteroids may be relevant for differentiation of glia. Gago et al. ([@B37]) showed that the formation of the 5α-reduced metabolite of P, dehydroprogesterone (DHP), is fivefold higher in fully differentiated oligodendrocytes compared to oligodendrocyte progenitor cells. This suggests that the acquisition of the neurosteroids biosynthetic capacity is a marker of glial differentiation. In addition, the reaction catalyzed by 3α-HSD involves the replacement of a carbonyl with a hydroxyl group, leading to the formation of metabolites that are potent modulators of non-classical steroid receptors (see below). Some biochemical studies demonstrated that 3α-HSD is distributed in various regions of the rodent brain (Khanna et al., [@B67]; Mellon et al., [@B114]; Agis-Balboa et al., [@B1]), where it is mainly localized in type 1 astrocytes (Melcangi et al., [@B104], [@B105]) and in oligodendrocytes (Melcangi et al., [@B105]). The 5α-R-3α-HSD activity is also present in the SC of the PNS (Melcangi et al., [@B101], [@B107], [@B109]; Yokoi et al., [@B156]). Therefore, the ability to synthesize or metabolize particular arrays of steroids seems to be region-specific in the different CNS areas and confined to glial cells (Mellon et al., [@B114]). In line with this hypothesis, the 5α-R activity in the myelin forming cells of the CNS and PNS (that is oligodendrocytes and SC, respectively) appeared different, being about four times higher in SC compared to oligodendrocytes (Melcangi et al., [@B107]). Thus, the presence of the 5α-R-3α-HSD enzymatic complex in oligodendrocytes and SC suggests that the locally formed neurosteroids might play a crucial role in the process of myelination (Melcangi et al., [@B102], [@B99]; Martini et al., [@B95]).

The neurosteroid 5α-pregnan-3α-ol-20-one, also named tetrahydroprogesterone or allopregnanolone (ALLO) is the most important hormonal steroid that was originally shown to act as a neurosteroid. It is synthesized through the action of the 5αR-3α-HSD, which converts P into DHP and subsequently, via a bidirectional reaction, into ALLO (see Figure [1](#F1){ref-type="fig"}, in SC). Interestingly, ALLO is able to modulate several neuronal cell functions. For instance, it is proven to be a neurogenic molecule, inducing a dose dependent significant increase in proliferation of rat neural progenitor cells and of human neural stem cells (Wang et al., [@B152]), or affecting cerebellar neurogenesis (Keller et al., [@B63]). Besides these studies revealing ALLO's actions on the neuronal compartment, several observations have suggested important roles for ALLO on glial cells. In this review we attempt to summarize the intriguing modulations and the therapeutic potential of the neurosteroid ALLO on the glial cells of the CNS and PNS.

![**Schematic representation showing ALLO, GABA and its receptors (GABA-A and GABA-B) acting in the bidirectional cross-talk between neurons and SC**. We propose the following hypothesis on the functional role of the GABAergic system in SC. GABA, coming from the neuronal compartment or produced by the SC (Magnaghi et al., [@B90]), may affect the paracrine cross-talk between these cells. The extracellular GABA might interact with the GABA-B receptor on the SC surface, decreasing their proliferation (Magnaghi et al., [@B86]). This challenge then diminishes the cAMP levels, reducing the myelin proteins expression (Magnaghi et al., [@B86]) and prompts the SC to start differentiation. The neurosteroid ALLO, which is produced by SC (Baulieu and Schumacher, [@B8]; Melcangi et al., [@B109]) allosterically activates the GABA-A receptor on the SC surface (Magnaghi et al., [@B87]). This modulates the expression and the responsiveness of the GABA-B receptor (Magnaghi et al., [@B87], [@B90]), and in turn its desensitization. Contemporarily, ALLO stimulates the SC proliferation (Perego et al., [@B125]), inducing other genomic effects such as the increase of myelin proteins (Melcangi et al., [@B108]; Magnaghi et al., [@B88]), and the rising of GAD and GABA levels (Magnaghi et al., [@B90]). The last effect, being a sort of autocrine mechanism, involving enhanced cAMP levels and the PK-A pathway. Collectively, these findings suggest that an autocrine mechanism involving ALLO and GABA is particularly relevant for the control of SC proliferation/differentiation, and may be considered the result of a balanced activation of GABA-A or GABA-B receptors on SC.](fendo-02-00103-g001){#F1}

Mechanism of Action of Neurosteroids
====================================

Neurosteroids exert complex effects in the nervous system through "classic" and "non-classic" actions. The "classic" genomic action consists of the modulation of their target cells by regulating gene transcription after binding to nuclear receptors (Slater et al., [@B140]). By contrast, the rapid "non-classic" action involves the modulation of neurotransmitter receptors, that is γ-aminobutyric acid (GABA), *N*-Methyl-[d]{.smallcaps}-aspartate (NMDA), 5-hydroxytryptamine type 3 (5HT~3~) and σ-receptors (Lambert et al., [@B74]; Rupprecht et al., [@B129]; Monnet and Maurice, [@B119]; Sedlacek et al., [@B135]) and the activation of novel putative membrane receptors for steroids (Hammes and Levin, [@B45]; Dressing et al., [@B30]; Levin, [@B83]). Some of these receptors have been found in glial cells (see Tables [1](#T1){ref-type="table"}-- [3](#T3){ref-type="table"}).

###### 

**Distribution of major classic and non-classic receptors for neurosteroids in astrocytes**.

  Classic intracellular receptors                  Non-classic membrane receptors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  ------------------------------------------------ ------------------------------------------------------------------------------------------ -------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------- ---------------------------------------------
  Rat glial culture (Jung-Testas et al., [@B57])   Pig brain areas (Langub and Watson, [@B78])                                                Primate prefrontal cortex (Finley and Kritzer, [@B35])   Mouse corpus callosum (Berger et al., [@B14])                                                                                                                                                                                                  Rat celebral cortex (Conti et al., [@B28]), spinal cord slice (Ziak et al., [@B157]), and injured rat hippocampus (Krebs et al., [@B70])   Rat glial culture (Kuo et al., [@B71])   Rat spinal cord (Labombarda et al., [@B72])
                                                   Rat brain (Azcoitia et al., [@B5]; Cardona-Gomez et al., [@B23]; Milner et al., [@B117])   Rat glial culture (Jung-Testas et al., [@B57])           Rat hypothalamus (Israel et al., [@B53]), hippocampus (Macvicar et al., [@B84]; Fraser et al., [@B36]; Kang et al., [@B61]) spinal cord (Chvatal et al., [@B26]; Pastor et al., [@B124]), optic nerve astrocytes (Butt and Jennings, [@B21])   Human celebral cortex (Conti et al., [@B27])                                                                                                                                        
                                                   Rat glial culture (Jung-Testas et al., [@B57]; Santagati et al., [@B132])                                                                           Rat glial culture (Kettenmann et al., [@B65]; Backus et al., [@B6]; Bormann, [@B16]; Rosewater and Sontheimer, [@B128]; Hosli et al., [@B51]; Matsutani and Yamamoto, [@B96])                                                                  Mouse cortex (Lalo et al., [@B73]) and neocortex (Schipke et al., [@B134])                                                                                                          
                                                                                                                                                                                                       Human brain and human glial culture (Lee et al., [@B80],[@B81])                                                                                                                                                                                Human glial culture (Lee et al., [@B80],[@B81])                                                                                                                                     

###### 

**Distribution of major classic and non-classic receptors for neurosteroids in oligodendrocytes**.

  Classic intracellular receptors                  Non-classic membrane receptors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  ------------------------------------------------ --------------------------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ---------------------------------------------
  Rat glial culture (Jung-Testas et al., [@B57])   Rat glial culture (Jung-Testas et al., [@B57]; Santagati et al., [@B132])   Primate prefrontal cortex (Finley and Kritzer, [@B35])   Mouse corpus callosum (Berger et al., [@B14])                                                                                                                                            Rat spinal cord slice (Ziak et al., [@B157]), cerebellum and corpus callosum slices (Karadottir et al., [@B62]), and optic nerve (Salter and Fern, [@B131]; Micu et al., [@B115])   --   Rat spinal cord (Labombarda et al., [@B72])
                                                                                                                               Rat glial culture (Jung-Testas et al., [@B57])           Rat spinal cord (Pastor et al., [@B124]) and optic nerve (Borges et al., [@B15]) Mouse glial culture (Gilbert et al., [@B43]; Kettenmann et al., [@B66]; Hoppe and Kettenmann, [@B48])   Rat glial culture (Wang et al., [@B151])                                                                                                                                                 
                                                                                                                                                                                        Culture of mouse (Von Blankenfeld et al., [@B150]; Kirchhoff and Kettenmann, [@B68]) and rat (Belachew et al., [@B9]; Williamson et al., [@B155]) precursor cells.                                                                                                                                                                                                                

###### 

**Distribution of major classic and non-classic receptors for neurosteroids in Schwann cells**.

  Classic intracellular receptors                                                                                                 Non-classic membrane receptors                                                                                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- --------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------ ---- ----
  Rat SC in culture (Jung-Testas et al., [@B59]; Jung-Testas and Baulieu, [@B56]; Thi et al., [@B144]; Magnaghi et al., [@B89])   Rat SC in culture (Jung-Testas and Baulieu, [@B56])   Rat SC in culture (Magnaghi et al., [@B89])   Rat SC in culture (Melcangi et al., [@B108]; Magnaghi et al., [@B87])   Guinea pig SC in culture (Fink et al., [@B34])   --   --
  Rat sciatic nerve (Magnaghi et al., [@B88])                                                                                                                                                                                         Rat sciatic nerve (Melcangi et al., [@B108]; Magnaghi et al., [@B87])   Giant squid SC (Evans et al., [@B32], [@B33])         

Allopregnanolone is a potent modulator of the GABA type A (GABA-A) receptor (Majewska et al., [@B93]; Majewska, [@B92]; Lambert et al., [@B75]). In fact, the most important and well-characterized "non-classic," non-genomic action of neurosteroids is represented by the ALLO's activation of GABA-A receptor functions (Majewska et al., [@B93]; Rupprecht and Holsboer, [@B130]; Lambert et al., [@B76]). Interestingly, ALLO's mechanism of action on GABA-A receptor is concentration dependent. Indeed, in the low nanomolar aqueous concentration ALLO acts allosterically, enhancing the action of the natural ligand GABA, while at higher concentration (micromolar range) ALLO directly gates the GABA-A receptor channel complex (Callachan et al., [@B22]; Puia et al., [@B126]). However, it has been shown that neurosteroids may directly gate GABA-A receptors also at lower concentration, around 100 nM, but the kinetic of this receptor activation is relatively slow (Shu et al., [@B137]).

The GABA-A receptor is a member of the ligand-gated ion channel family, permeable to chloride ions and composed of five subunits drawn from a repertoire of 19 isoforms (that is α1--6, β1--3, γ1--3, δ, ε, π, ¸, ρ1--3; Whiting et al., [@B154], [@B153]; Lambert et al., [@B76]). The GABA-A receptor is blocked by bicuculline and picrotoxin, but channel opening is enhanced by benzodiazepines, barbiturates, anesthetics and also neurosteroids (Park-Chung et al., [@B123]; Belelli and Lambert, [@B11]). Interestingly, the GABA-A receptor modulation exerted by neurosteroids is enantioselective and is partially dependent upon the receptor subunit composition. For this reason several studies were aimed at elucidating the putative neurosteroids external binding sites (Lambert et al., [@B76]). Although no special requirement concerning the nature of the α and β subunits seems to be essential to confer sensitivity to neurosteroids (Belelli et al., [@B10]), a receptor composed of one α (α2--5) assembled with β3 and γ2S subunits gives consistent potentiation of ALLO-mediated GABA-activated currents (Hosie et al., [@B49]). Moreover, γ2 subunits confer more sensitivity than γ1 or γ3 (Belelli et al., [@B10]), while δ subunit potentiates the action of the 5α-3α-reduced neurosteroids (Mihalek et al., [@B116]; Belelli et al., [@B10]). The extrasynaptic GABA-A receptor incorporating the δ subunit, indeed, is an important and highly sensitive target of neurosteroids (Lambert et al., [@B77]), implicating the δ-containing receptors as the preferred target for the action of neurosteroids. Nevertheless, the δ subunit seems to primarily influence the transduction of neurosteroid signals rather than engage directly in binding (Hosie et al., [@B49]).

Neurosteroids might also indirectly target the receptor function by regulating the transcription of some GABA-A receptor subunits, thus altering the GABA-A inhibitory activity for a prolonged time (Maguire and Mody, [@B91]). Neurosteroids might also interact with protein kinase or phosphatases, which in turn act on GABA-A subunits altering the entire receptor function (Belelli and Lambert, [@B11]). Likewise, phosphorylation of GABA-A receptors by protein kinase C (PK-C) influences the sensitivity to neurosteroids (Brussaard and Koksma, [@B20]; Vergnano et al., [@B149]).

Beside the external binding sites of GABA-A receptor, some recent evidence supports a novel hypothesis suggesting that neurosteroids require a membranous route of access to transmembrane-domain binding sites within GABA-A receptor (Shu et al., [@B137]; Akk et al., [@B2]; Hosie et al., [@B50]; Chisari et al., [@B25]). Once neurosteroids reach the site of action they may diffuse through the plasma membrane to directly bind the GABA-A receptor, rather than interacting with external binding sites of the receptor. This is a low-affinity receptor interaction that might depend on the lipid composition of the cell membrane. Neurosteroids may be also retained in the intracellular compartment and then re-supply the plasma membrane with ligands able to modulate the GABA-A receptor at later times, so that the rate of this transport can alter the kinetics of neurosteroids actions (Akk et al., [@B2]).

The proposed mechanisms of ALLO's action, however, may be in principle complementary to the classic genomic effects. Indeed, an indirect action of ALLO involving the classic progesterone receptor (PR) should not be totally excluded. In such a scenario, ALLO's action closely depends on its retro-conversion to DHP, operated by enzyme 3α-HSD (Martini et al., [@B95]), which may then stimulate the PR generating a classic genomic effect. In comparison to ALLO's rapid interaction with GABA-A receptors, the PR-mediated mechanism shows slower kinetics and lasts for a longer time.

Finally, concerning the ALLO interaction with the GABAergic system, its putative ability to interact with the metabotropic GABA-B receptor should not be totally excluded, although the evidence that such an interaction effectively occurs is not clearly provided. GABA-B receptor is a distinct, baclofen-sensitive, metabotropic receptor that is a member of the seven transmembrane G-protein-coupled receptor superfamily. GABA-B receptors may influence the activity of adenylate cyclase and/or modulate calcium and potassium channels activity (Bowery and Enna, [@B18]). In this regard, we have recently demonstrated *in vitro* a cross-correlation between the GABA-A and B receptors in SC (Magnaghi, [@B85]), and some of these effects are discussed below.

ALLO's Effect on Astrocyte
==========================

Neurosteroids are known to control the proliferation, cell shape, and gene expression of CNS astroglia (Garcia-Segura et al., [@B39], [@B40]; Jordan, [@B55]; Nichols, [@B121]). The cytoskeletal protein, glial fibrillary acidic protein (GFAP) is usually responsible for modulating astrocyte shape and motility (Laping et al., [@B79]). Many of the effects of neurosteroids on the expression and synthesis of GFAP are due to their active metabolites. For instance, the gene expression of GFAP in culture of astrocytes is inhibited by ALLO and stimulated by DHP, suggesting that different intracellular signaling pathways are likely to be involved in astrocytes proliferation (Melcangi et al., [@B113]). Nevertheless, it has been proposed that the ALLO's effects on astrocytes are mediated by the activation of GABA-A receptors, whose subunits are widely distributed in astrocytes (Bovolin et al., [@B17]; Hosli et al., [@B51]; Israel et al., [@B53]). The effects of neuroactive steroids have also been evaluated on ammonia-induced astrocyte swelling in culture, a phenomena that occurs early after some acute CNS pathologies such as ischemia and traumatic brain injury. Bender and Norenberg ([@B13]) showed that nanomolar concentration of ALLO diminishes the astrocyte swelling, likely via a GABA-A mechanism. These observations might be very useful for the development of new therapeutic approaches to treat the acute hyperammonemic syndromes and other associated pathological conditions (Bender and Norenberg, [@B13]).

Allopregnanolone seems to be also involved in the feedback mechanisms regulating the gonadal axis, and in particular the neuroendocrine function of the luteinizing-hormone-releasing hormone (LHRH). Herbison and collaborators provide the first evidence for a direct action of ALLO on postnatal LHRH neurons, suggesting a new mechanism by which fluctuating P levels may influence the secretory activity of these neurons in the female hypothalamus (Sim et al., [@B138]). At the cellular level, the increased ALLO concentration, typical of late pregnancy, has important physiological actions in repressing the electrical activity of specific magnocellular oxytocin neurons in the hypothalamus. Moreover, the fall in ALLO concentration prior to parturition equally impacts GABA-A receptor signaling in oxytocin neurons, as well as in the hippocampus and frontal cortex neurons, suggesting that ALLO's concentration changes during pregnancy are likely to exert a powerful regulatory influence upon neurotransmission in a variety of brain networks (Herbison, [@B46]).

However, paracrine mechanisms involving astrocyte cells may also be at the base of positive or negative feedback signals regulating the reproductive axis. Indeed, growth factors such as transforming growth factor α (TGFα), transforming growth factor β1 (TGFβ1) and β2 (TGFβ2), as well as basic fibroblast growth factor (bFGF) and insulin-like growth factor-I (IGF-I) are released by astrocytes and participate in the control of LHRH release (Melcangi et al., [@B106]; Ojeda and Ma, [@B122]). ALLO stimulates TGFβ1 gene expression in hypothalamic astrocytes, nevertheless also P and DHP proved able to exert an identical effect, suggesting that ALLO's action may imply an indirect mechanism mediated via PR (Melcangi et al., [@B97]).

ALLO's Effect on Oligodendrocyte
================================

In mature oligodendrocytes (the cells responsible for forming the central myelin) the progestagens neurosteroids regulate the gene expression of some important proteins, such as the myelin basic protein (MBP) and the 2′-3′-cyclic nucleotide-3-phospodiesterase (CNPase; Verdi and Campagnoni, [@B148]; Jung-Testas et al., [@B60]). The age-associated decline in MBP expression levels in 22- to 24-month-old male rats, for instance, was reversed by ALLO and DHP, still indicating a PR-mediated genomic mechanism (Ibanez et al., [@B52]). The progestagens involvement on MBP expression regulation in oligodentrocytes was demonstrated also in organotypic slice cultures of 7-day-old rat and mouse cerebellum (Ghoumari et al., [@B42]). This effect likely involves classic PR, since it was mimicked with the selective PR agonist R5020 and blocked with the PR antagonist mifepristone (Ghoumari et al., [@B42]). However, ALLO significantly stimulates MBP expression in 7-day-old rat and mouse cerebellum cultures, and this effect seemed to be mediated via GABA-A receptor activation. In accordance, the GABA-A antagonist bicuculline counteracts the ALLO stimulatory effect, confirming a GABA-A-mediated mechanism (Ghoumari et al., [@B42]). It is important to underline that some GABA-A receptor subunits are expressed in oligodendrocytes (Gilbert et al., [@B44]) and in oligodendrocyte progenitor cells (Kettenmann et al., [@B66]; Kirchhoff and Kettenmann, [@B68]). Gago et al. ([@B38]) observed that the neuroactive steroids and GABA signaling are responsible for the autocrine/paracrine loops controlling neuronal progenitors proliferation and differentiation. The neuronal progenitor polysialylated-neural cell adhesion molecule positive cells (PSA-NCAM^+^), indeed, possess several GABA-A receptor subunits (Nguyen et al., [@B120]; Gago et al., [@B38]), like the α1-5, β2, β3, and γ2 isoforms (Gago et al., [@B38]). Interestingly, GABA increased in a dose dependent manner the proliferation of these cells and the effect was bicuculline sensitive, suggesting a GABA-A-mediated mechanism. The effect on the PSA-NCAM^+^ proliferation was also mimicked by nanomolar concentration of ALLO. Moreover, P via its conversion in ALLO, proved able to stimulate the early PSA-NCAM^+^ progenitor proliferation (Gago et al., [@B38]).

Collectively, these findings suggest a pivotal role of ALLO and GABA in the development and maturation of oligodendrocytes (Ben-Ari, [@B12]; Gago et al., [@B38]).

ALLO's Effect on Microglia
==========================

Steroids exert anti-inflammatory actions in the peripheral tissues as well as in the brain, where they act mainly on microglial cells. In this regard, some efforts were addressed to study the neuroprotective role of estrogens and progesterone on microglial cells (Stone et al., [@B142]; Vegeto et al., [@B146], [@B145]; Drew and Chavis, [@B31]; Bruce-Keller et al., [@B19]). In parallel, several line of evidence showed that ALLO plays a neuroprotective role following different brain injury conditions, such as ischemic damage (Kelley et al., [@B64]), PTX-induced seizures (Singh et al., [@B139]) and oxygen-glucose deprivation (Ardeshiri et al., [@B3]). The concentrations of ALLO are also remarkably high in the fetal brain and further rise in response to acute hypoxia, representing an endogenous protective mechanism in the developing brain (Hirst et al., [@B47]). These effects might be generally ascribed to ALLO's regulation of anti-inflammatory cytokines and endogenous antioxidants, although only few evidences rely on the direct effect of ALLO on microglial cells. For instance, the endogenous concentration of ALLO in the brain is increased concomitantly to the lipopolysaccharides-induced tumor necrosis factor α (TNFα) production, which in turn inhibits TNFα levels (Ghezzi et al., [@B41]). ALLO also protects against apoptotic cell death in an *in vivo* model of rat prefrontal cortex injury, even if this effects were not totally referred to a microglial cell disregulation (Djebaili et al., [@B29]).

ALLO's Effect on SC
===================

Over the last few decades a large body of evidence has accumulated from investigations into the potential effects that neurosteroids exert on SC, which are the cells ensheathing axons and forming the myelin in the PNS (Jessen and Mirsky, [@B54]). The first studies started when Baulieu and colleagues focused their attention on neurosteroid biosynthesis, analyzing primarily the peripheral nerves, such as the sciatic nerve, and the SC (Jung-Testas et al., [@B58]). The progestagens, P and its 5α-derivatives (DHP and ALLO) have been studied *in vivo*, demonstrating that they are able to modulate several biochemical and morphological parameters of the PNS (Melcangi et al., [@B112]; Magnaghi et al., [@B88]). For instance, progestagens stimulated the expression of specific peripheral myelin proteins, such as the myelin protein zero (P0) and the peripheral myelin protein 22 (PMP22), in the sciatic nerve of young and old male rats (Melcangi et al., [@B107], [@B108], [@B112]; Magnaghi et al., [@B88]). Moreover, they reduced myelin abnormalities and fibers loss in aged sciatic nerve (Azcoitia et al., [@B4]), promoting re-myelination after cryolesion (Koenig et al., [@B69]), transection (Melcangi et al., [@B110]), or crush injury (Roglio et al., [@B127]). Mifepristone (RU38486), a classic PR antagonist, was recently studied because of its ability in decreasing the PMP22 overexpression in a rat model of peripheral inherited neuropathy (i.e., the Charcot Marie Tooth type 1A, CMT1A; Sereda et al., [@B136]). These results lead to the conclusion that PR likely participates in the control of specific peripheral myelin proteins, such as P0 and PMP22 (Magnaghi et al., [@B88]). Nevertheless, *in vitro* studies showed that ALLO, besides the ability of increasing P0 mRNA levels, is the main neurosteroid able to stimulate the levels of PMP22 mRNA and protein (Melcangi et al., [@B108], [@B111]; Magnaghi et al., [@B88]).

Allopregnanolone is a potent modulator of GABA-A receptor, which subunits are widely distributed in SC (Melcangi et al., [@B108]; Magnaghi et al., [@B87]). SC in culture, indeed, express the messengers for several GABA-A receptor subunits, that is α 2 and 3, β 1, 2, and 3 (Melcangi et al., [@B108]; Magnaghi et al., [@B87]).

Therefore, to investigate if the effect of ALLO on PMP22 expression was mediated by interaction with GABA-A receptors, ALLO's stimulation was mimicked with specific GABA-A ligands. Bicuculline, a specific GABA-A antagonist, abolishes the effect of ALLO on PMP22 expression levels, whereas muscimol (a specific GABA-A agonist) mimics ALLO's action (Magnaghi et al., [@B88], [@B87]), confirming the hypothesis that the expression of PMP22 in SC is under the control of GABA-A receptors. However, ALLO's action via the GABAergic system in SC is even more complex, because it also involves the GABA-B receptor and the endogenous GABA neurotransmitter (see Figure [1](#F1){ref-type="fig"} for details).

Recent observations obtained by reverse transcriptase-polymerase chain reaction, western blot and immunohistochemistry analyses confirmed the presence of GABA-B receptor subunits (1a, 1b, and 2) in SC, where the functional receptor was proved to be negatively coupled to the adenylate cyclase system (Magnaghi et al., [@B86]). The activation of the GABA-B receptor in SC influences cell proliferation, as demonstrated with baclofen treatment that counteracted the forskolin-induced SC proliferation at 5 days *in vitro* (Magnaghi et al., [@B86]); at the same time point also the percentage of BrdUrd immunopositive SC was reduced (Magnaghi et al., [@B86]). Since the activation of the adenylate cyclase system potentially regulates SC proliferation (Lee et al., [@B82]; Mirsky and Jessen, [@B118]), we speculated that GABA-B-induced decrease in cAMP levels may affect the cell proliferation (Magnaghi et al., [@B86]). Notably, changes in cAMP levels in SC may also influence the expression of specific myelin proteins (Suter et al., [@B143]; Scherer et al., [@B133]; Lee et al., [@B82]). In agreement, GABA-B activation decreases the expression of some important myelin proteins, like P0, PMP22 as well as other proteins, like connexin 32 and the myelin associated glycoprotein (MAG; Magnaghi et al., [@B86]).

Investigating the putative effects of neurosteroids on GABA-B receptor subunits expression in the SC *in vitro*, it was also shown that ALLO controls the expression of different GABA-B receptor subunits (Magnaghi et al., [@B87]). The expression profile was biphasic; after 4 h of exposure ALLO produces a robust stimulation of the mRNA of all three subunits, -1a, -1b, and -2, while at 24 h of exposure ALLO decreased the expression of -1b and -2 subunits (Magnaghi et al., [@B87]). Since ALLO's effect on GABA-B receptor expression was mimicked by muscimol and GABA, it was hypothesized that ALLO regulates GABA-B receptor via a GABA-A-mediated mechanism (Magnaghi et al., [@B87]; Magnaghi, [@B85]). The intracellular pathways downstream of this interaction is rather complicated and presently not completely identified, however a possible hypothesis is proposed below. After 24 h of exposure, P and DHP give rise to a GABA-B receptor modulation similar to that induced by ALLO. The longer time required leads to the hypothesis that P and DHP effects are due to their 5α-R-3α-HSD mediated conversion into ALLO (Magnaghi et al., [@B87]; Magnaghi, [@B85]). Therefore, GABA-B subunits expression may be differently influenced, mainly by ALLO via a GABA-A-mediated mechanism, but also by its precursors P and/or DHP after 5α-R-3α-HSD conversion into ALLO.

Most of the effects exerted by ALLO in SC were achieved at nanomolar concentration, involving an allosteric interaction that necessarily entails the presence of the endogenous ligand GABA. To make the issue even more puzzling, the presence of GABA and its synthetic machinery was thus demonstrated in SC. In particular the glutamic acid decarboxylase of 67 kDa (GAD67), a key enzyme for GABA synthesis, was shown to be expressed in SC. Acting in a way that resemble an autocrine loop, ALLO (10 nM) increased the levels of GAD67 in SC, thus stimulating GABA synthesis and providing the natural ligand for GABA-A receptor (Magnaghi et al., [@B90]).

Finally, in line with this hypothesis, it was recently demonstrated that SC *in vitro* possess a functionally active glutamate uptake system able to provide glutamate as a precursor for the synthesis of GABA (Perego et al., [@B125]). Indeed, it was first demonstrated that SC express the excitatory amino acid transporter 1 (EAAC1) in the plasma membrane and in intracellular vesicular compartments of the endocytic recycling pathway. Interestingly, EAAC1 activity can be modulated by exposure of SC to ALLO 10 nM. The transporter up-regulation by ALLO was rapid, did not involve protein neo-synthesis and was prevented by actin depolymerization. The modulation exerted by ALLO involved GABA-A receptor and PK-C activation, promoting the exocytosis of the EAAC1 transporter from intracellular stores to the SC membrane (in actin-rich cell tips), and modifying the morphology of SC processes. The evidence that EAAC1 transporter controls the ALLO-mediated effects on SC proliferation was also provided (Perego et al., [@B125]).

Downstream Mechanism Following ALLO's Activation of GABA-A Receptor: Is the Puzzle Unpuzzled?
=============================================================================================

Several attempts in the literature tried to explain the intracellular molecular mechanism downstream to ALLO's allosteric activation of GABA-A receptor, in neurons as well as in central and/or peripheral glial cells. For instance, in the developing rat cortex, GABA-A receptor activation leads to the opening of L-type voltage-gated calcium channels, resulting in an increase of calcium influx, which in turn leads to phosphorylation and activation of the transcription factor cAMP response element-binding protein (CREB) and finally controls neuronal nitric oxide synthase and brain derived neurotrophic factor expression (Mantelas et al., [@B94]). However, it should be underlined that the presence of endogenous GABA is the first precondition for ALLO's allosteric action. The synthesis of GABA was previously shown in astrocytes and oligodendrocytes, and very recently also in SC (Magnaghi et al., [@B90]).

Therefore, the interaction among the neurosteroid ALLO, GABA-A, and GABA-B receptors is relevant, at least in the PNS, for the bidirectional cross-talk between neurons and SC (Figure [1](#F1){ref-type="fig"}). GABA, coming from the neuronal compartment, or produced by SC (Magnaghi et al., [@B90]) may affect the paracrine interplay between these cells. In fact, data obtained with the specific GABA-B ligand baclofen suggest that extracellular GABA might interact with GABA-B receptors on SC, decreasing their proliferation, the cAMP levels and the myelin proteins expression. This effect promotes SC differentiation. ALLO produced by SC (Baulieu and Schumacher, [@B8]; Melcangi et al., [@B109]) via a direct action on GABA-A receptor modulates the GABA-B receptor expression, distribution and responsiveness, and in turn its desensitization. Contemporarily, ALLO may increase some myelin proteins expression in SC. Muscimol mimicked this effect on SC, further supporting that GABA-A might also participate in the control of the SC proliferation/differentiation (Figure [1](#F1){ref-type="fig"}).

However, the nature of the signaling pathways downstream to the ALLO's allosteric modulation of GABA-A receptor is still debated. We suggest an involvement of the protein kinase A (PK-A) pathway, which through enhanced cAMP levels and CREB phosphorylation, modulates the allosteric action of ALLO at the GABA-A receptor (Magnaghi et al., [@B90]). However, other protein kinases should be also considered. In fact, the allosteric ALLO's modulation of GABA-A receptor, regulating glutamate uptake via EAAC1 transporter, is dependent by a PK-C activation, as confirmed by the very recent analysis of the pharmacological profile (Perego et al., [@B125]). Whether this relatively rapid ALLO's action on GABA-A receptor in glial cells may lead to ion channels opening, as occur in neuronal cells, should not be totally excluded and deserves further investigation.

Conclusion
==========

In this review we focused our attention on the putative effects of ALLO on the glial cells of the CNS and PNS, with a particular emphasis on ALLO's regulation of glial physiology in normal and/or pathological conditions. The mechanism by which ALLO exerts these controls is part of the "non-genomic" action of steroids, involving the rapid modulation of neurotransmitter receptors such as the GABA receptors. However, ALLO's action on GABA-A receptor somehow involves downstream "genomic" mechanisms that are yet to be completely elucidated. In SC these intracellular mechanisms imply the activation of PK-A and PK-C signaling pathways, which in turn may determine the physiologic control of SC proliferation/differentiation. Nevertheless, an involvement of other intracellular pathways, for instance ion calcium channels, as observed in rat neuroprogenitor cells and human neural stem cells (Wang et al., [@B152]), should be further investigated.
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